Figure 4: Parasite myosin A (PfMyoA) is a cellular target for PfPKG.
(a,b) Box plot display of the quantitative changes in abundance of (a) a non-phosphorylated PfMyoA peptide derived from wild-type and PfPKGT618Q parasites treated with vehicle or Compound 2 (2 μM; Comp 2) and (b) of a peptide containing the serine-19 phosphorylation of PfMyoA. (c,d) Western blot of parasite lysates prepared from (c) wild-type parasites and (d) PfPKGT618Q parasites, treated with vehicle or Comp 2 (2 μM). The blots were probed either with a phospho-specific antibody to phosphorylated serine-19 on PfMyoA (MyoA-pS19) or with an antibody against PfMyoA as a loading control. The western blot data shown are representative of three independent experiments and the quantification of n=3 experiments ±s.e.m. Student’s paired t-test was applied to test statistical significance ***P<0.001.
